期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
重组HIV-1腺病毒载体活疫苗的冻干保护剂研究 被引量:10
1
作者 张一折 滕洪刚 +3 位作者 吕帅然 姜春来 于湘晖 孔维 《中国生物制品学杂志》 CAS CSCD 2007年第2期104-106,共3页
目的研制重组HIV-1腺病毒载体活疫苗的冻干保护剂。方法在重组HIV-1腺病毒载体活疫苗中加入不同配比的保护剂,在适宜条件下制备成冻干剂型。根据冻干后外观、病毒滴度和热稳定性试验等结果,筛选出冻干保护剂的最适配方。结果以人血白蛋... 目的研制重组HIV-1腺病毒载体活疫苗的冻干保护剂。方法在重组HIV-1腺病毒载体活疫苗中加入不同配比的保护剂,在适宜条件下制备成冻干剂型。根据冻干后外观、病毒滴度和热稳定性试验等结果,筛选出冻干保护剂的最适配方。结果以人血白蛋白、海藻糖、甘露醇、右旋糖苷和蔗糖等成分按比例配伍制备的保护剂,对重组HIV-1腺病毒载体活疫苗显示了较好的保护作用。冻干前后疫苗病毒感染性滴度下降在0.17LogCC ID50/ml以内;37℃放置1周,滴度下降0.3LogCC ID50/ml左右;37℃放置3周后,滴度下降约为0.6LogCC ID50/ml。而无保护剂的液体疫苗对照于37℃放置1周,滴度下降近2.5个LogCC ID50/ml。结论以人血白蛋白、海藻糖、甘露醇、右旋糖苷和蔗糖等配伍而制备的保护剂效果较好。 展开更多
关键词 hiv-1腺病毒载体活疫苗 冷冻干燥 保护剂
下载PDF
The Strengths, Weaknesses, Opportunities and Threats (SWOT) Analysis of <i>Mycobacterium tuberculosis</i>: A Systematic Review 被引量:1
2
作者 Michael Oluyemi Babalola 《Journal of Tuberculosis Research》 2015年第4期184-205,共22页
Background: Mycobacterium tuberculosis, the etiology of pulmonary and extra pulmonary tuberculosis is taunted to have predated the existence of mankind, and science has elucidated its presence in old Egyptian’ mummie... Background: Mycobacterium tuberculosis, the etiology of pulmonary and extra pulmonary tuberculosis is taunted to have predated the existence of mankind, and science has elucidated its presence in old Egyptian’ mummies, as it continues to evade current antibiotic treatments, wreck the havoc and decimate human populations. Presented here, are the Strengths, Weaknesses, Opportunities and Threats (SWOT) analysis of Mycobacterium tuberculosis, and the first proposal for the application of this innovative concept in the field of Tuberculosis research, to proffer holistic platform, focused knowledge, and strategies at undermining the prowess of the tubercle bacilli and overcoming its scourge. Materials and Methods: A systematic review was carried out to mine data on the strengths, the weaknesses, the opportunities and threats to M. tb, by review of several publications using meaningful theme and specific search phrases on the subject. Results: Strengths of Mycobacterium tuberculosis include: possession of abundant cell wall mycothiol;M. tb is highly contagious and requires low infectious dose (ID50) to establish infection;ability to specifically target and replicate in the host’ macrophages;ability to establish extrapulmonary multiorgan involvement;dual polymorphism i.e. existence in both an actively replicating form as well as or latent state;assumption of variable metabolic states;delayed seeding from the lungs of the replicating bacteria cells to the mediastinal lymph nodes;delayed macrophage apoptosis prior to bacterial growth and ultimate cellular necrosis;ability to shift to glyoxylate pathway during lipid metabolism in lieu of glucose during persistence phase in the host. Weaknesses of M. tuberculosis include: the requirement for growth of a membrane protein called Rv3671c during in vivo replication for survival in the acidic milieu of the macrophages and phagosome;M. tb is a fastidious slow growing bacterium with long generation time;establishment of productive infection in less than 10% of infected subjects;the bacterium is strictly an intracellular aerobic pathogen;and variable bacteria level of adenosine triphosphate. Opportunities harnessed by M. tb include: development and spread of resistant strains owing to inadequate and inappropriate drug treatment;limited efficacy and use of BCG Vaccine;MDR-TB is under-diagnosed in children;pathogenic synergy of coinfection of the Human Immunodeficiency Virus (HIV) and Mycobacterium tuberculosis (MTB);difficulty of TB screening in HIV-infected persons;immune status of the host;immigration;slow response of the cellular immune response to M. tbwhich enables constant endogenous reinfection of the host;anatomical vulnerability of the lungs;aerosols by inspired air is crucial for latent tuberculosis infection. Threats to M. tuberculosis include: the development and use of sensitive combination of microbiological tests as the gold-standard in HIV infected patients;annual TB test;selective isolation of TB patients by reintroduction of sanatoria;prioritizing genomic drug targets;sustenance of the global TB funds;development of potent vaccine;live imaging using computer tomography and positron electron tomography to characterize active TB in lesions;development and application of Infecton for imaging deep seated infections. 展开更多
关键词 SWOT ANALYSIS Mycobacterium tuberculosis Mycothiols GLYOXYLATE Pathway Rv3671c hiv COINFECTION Lungs Vulnerability live Imaging Infecton vaccine
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部